News for ATNX Stock

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update Athenex Announces a Reverse Stock Split Athenex Announces MHRA Decision on Oral Paclitaxel Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer Athenex Exits 503B Sterile Compounding Business Athenex Announces Positive Results of Special Stockholder Meeting Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference Athenex Announces Receipt of Positive Nasdaq Listing Determination Athenex Provides Third Quarter 2022 Financial Results and Business Update Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022 Athenex Files Definitive Proxy Statement for Special Stockholder Meeting Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants Athenex Provides Second Quarter 2022 Financial Results and Business Update Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022 Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd. Athenex to Participate in Truist Securities Cell Therapy Symposium Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC) Athenex Provides First Quarter 2022 Financial Results and Business Update Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022 Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022 Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022 Athenex Announces Appointment of Chief Financial Officer Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021 Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition Athenex Provides Third Quarter 2021 Corporate and Financial Update Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021 Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021 Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021 Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit Athenex Provides Second Quarter 2021 Corporate and Financial Update Athenex Announces Additional Licensing Agreements for Tirbanibulin Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021 Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting Athenex Provides First Quarter 2021 Corporate and Financial Update Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021 Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin) Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021 Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin) CEO Dr. Johnson Lau Recuperating from COVID at Home CEO Dr. Johnson Lau Contracts COVID-19 Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020 Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC) Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers Athenex, Inc. Announces Proposed Public Offering of Common Stock Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020 Athenex Announces $225 Million Loan Agreement with Oaktree Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update